Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:29 PM
Ignite Modification Date:
2025-12-24 @ 11:29 PM
NCT ID:
NCT03317756
Eligibility Criteria:
Inclusion Criteria:
* Have a patient-reported diagnosis of RA
* Most recent RAPID3 \> 12 collected in the last 6 months
* Have not changed RA medication in the last 6 months
* Taking medications that are commonly used in RA (e.g. methotrexate, sulfasalazine, hydroxychloroquine (plaquenil), leflunomide (arava), etanercept (enbrel), adalimumab (Humira), tofacitinib (xeljanz), actemra (tocilizumab), sarilumab (Kevzara) , infliximab (remicade), golimumab (Simponi), rituximab (rituxan), abatacept (Orencia), and certolizumab (Cimzia))
Exclusion Criteria:
* Does not meet inclusion criteria
* Age \< 18
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03317756
Study Brief:
Protocol Section:
NCT03317756